ArticleFrontiers in immunology2026
Integrating metagenomics, transcriptomics, and molecular docking to reveal core gene biomarkers and gut microbiota regulatory mechanisms in tuberculous meningitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tuberculous meningitis (TBM) is a severe extrapulmonary tuberculosis with high mortality and neurological sequelae, while the role of gut microbiota and its metabolites in TBM pathogenesis remains poorly understood. This study aimed to characterize gut microbiota alterations in TBM patients and elucidate the "microbiota-metabolite-gene" regulatory axis. Methods: Fecal samples from 11 TBM patients and 11 healthy controls were subjected to 16S rRNA sequencing. Core target genes were identified via differential expression screening, machine learning, immune infiltration analysis and gene set enrichment analysis based on the public GSE40586 dataset. The regulatory axis was constructed by database prediction and molecular docking, and the regulatory effect was verified by Results: TBM patients exhibited significant gut dysbiosis. Two core genes (PIK3CB and JAK2) were identified, which were positively correlated with pro-inflammatory immune cells and enriched in bacterial infection pathways. The constructed regulatory axis showed that upregulated gut bacteria produced bile acid metabolites targeting PIK3CB/JAK2, with strong binding affinity verified by molecular docking. Conclusion: This study identifies a "gut microbiota-bile acid-PIK3CB/JAK2" regulatory axis in TBM, thus providing novel insights into gut-brain crosstalk and potential diagnostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.